Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
71
NUVB Quote, Financials, Valuation and Earnings
Last price:
$9.42
Seasonality move
:
-4.64%
Day range:
$9.26 - $9.56
52-week range:
$1.54 - $9.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
119.37x
P/B ratio:
9.89x
Volume:
3.6M
Avg. volume:
8.8M
1-year change:
233.33%
Market cap:
$3.2B
Revenue:
$7.9M
EPS (TTM):
-$0.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$30.8M | -$0.15 | 470.48% | -72.75% | $11.25 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$157.3M | -$0.16 | 9693.67% | -93.1% | $66.00 |
|
GRAL
GRAIL, Inc.
|
$35.4M | -$3.27 | 10.23% | -1.26% | $105.00 |
|
INDV
Indivior PLC
|
$261.9M | $0.41 | 2.76% | 323.75% | $37.86 |
|
NKTR
Nektar Therapeutics
|
$10.1M | -$2.59 | -64.24% | -1474.64% | $114.43 |
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.30 | -- | -27.21% | $53.56 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$9.40 | $11.25 | $3.2B | -- | $0.00 | 0% | 119.37x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$70.16 | $66.00 | $9.5B | -- | $0.00 | 0% | 11.29x |
|
GRAL
GRAIL, Inc.
|
$91.59 | $105.00 | $3.6B | -- | $0.00 | 0% | 22.62x |
|
INDV
Indivior PLC
|
$36.21 | $37.86 | $4.5B | 36.05x | $0.00 | 0% | 3.87x |
|
NKTR
Nektar Therapeutics
|
$44.49 | $114.43 | $769.7M | -- | $0.00 | 0% | 45.88x |
|
TERN
Terns Pharmaceuticals, Inc.
|
$41.52 | $53.56 | $3.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
38.98% | 0.827 | 16.41% | 8.18x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
61.15% | 4.654 | 15.55% | 4.74x |
|
GRAL
GRAIL, Inc.
|
2.55% | 4.765 | 2.74% | 7.26x |
|
INDV
Indivior PLC
|
238.93% | 1.044 | 11.83% | 0.73x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | 0.860 | 0.16% | 19.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$9.2M | -$56.4M | -43.02% | -52.16% | -430.14% | -$60.9M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$250.1M | $44.1M | 2.57% | 7.7% | 17.2% | $13M |
|
GRAL
GRAIL, Inc.
|
-$17.3M | -$125.3M | -16.4% | -16.84% | -346.17% | -$63.6M |
|
INDV
Indivior PLC
|
$252M | $99M | 130.39% | 14.29% | 31.53% | -$62.4M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
Nuvation Bio, Inc. vs. Competitors
-
Which has Higher Returns NUVB or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of 6.29%. Nuvation Bio, Inc.'s return on equity of -52.16% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M ARWRArrowhead Pharmaceuticals, Inc.97.51% -$0.18 $1.2B -
What do Analysts Say About NUVB or ARWR?
Nuvation Bio, Inc. has a consensus price target of $11.25, signalling upside risk potential of 19.68%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $66.00 which suggests that it could fall by -5.93%. Given that Nuvation Bio, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Nuvation Bio, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is NUVB or ARWR More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.
-
Which is a Better Dividend Stock NUVB or ARWR?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or ARWR?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 119.37x versus 11.29x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.119.37x -- $13.1M -$55.8M ARWRArrowhead Pharmaceuticals, Inc.11.29x -- $256.5M $16.1M
-
Which has Higher Returns NUVB or GRAL?
GRAIL, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of -245.83%. Nuvation Bio, Inc.'s return on equity of -52.16% beat GRAIL, Inc.'s return on equity of -16.84%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M GRALGRAIL, Inc.-47.91% -$2.46 $2.3B -
What do Analysts Say About NUVB or GRAL?
Nuvation Bio, Inc. has a consensus price target of $11.25, signalling upside risk potential of 19.68%. On the other hand GRAIL, Inc. has an analysts' consensus of $105.00 which suggests that it could grow by 14.64%. Given that Nuvation Bio, Inc. has higher upside potential than GRAIL, Inc., analysts believe Nuvation Bio, Inc. is more attractive than GRAIL, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 GRALGRAIL, Inc.2 2 0 -
Is NUVB or GRAL More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison GRAIL, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NUVB or GRAL?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GRAIL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. GRAIL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or GRAL?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than GRAIL, Inc. quarterly revenues of $36.2M. Nuvation Bio, Inc.'s net income of -$55.8M is higher than GRAIL, Inc.'s net income of -$89M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while GRAIL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 119.37x versus 22.62x for GRAIL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.119.37x -- $13.1M -$55.8M GRALGRAIL, Inc.22.62x -- $36.2M -$89M
-
Which has Higher Returns NUVB or INDV?
Indivior PLC has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of 13.38%. Nuvation Bio, Inc.'s return on equity of -52.16% beat Indivior PLC's return on equity of 14.29%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M INDVIndivior PLC80.26% $0.33 $149M -
What do Analysts Say About NUVB or INDV?
Nuvation Bio, Inc. has a consensus price target of $11.25, signalling upside risk potential of 19.68%. On the other hand Indivior PLC has an analysts' consensus of $37.86 which suggests that it could grow by 4.55%. Given that Nuvation Bio, Inc. has higher upside potential than Indivior PLC, analysts believe Nuvation Bio, Inc. is more attractive than Indivior PLC.
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 INDVIndivior PLC5 0 0 -
Is NUVB or INDV More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Indivior PLC has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.185%.
-
Which is a Better Dividend Stock NUVB or INDV?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Indivior PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Indivior PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or INDV?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than Indivior PLC quarterly revenues of $314M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Indivior PLC's net income of $42M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Indivior PLC's PE ratio is 36.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 119.37x versus 3.87x for Indivior PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.119.37x -- $13.1M -$55.8M INDVIndivior PLC3.87x 36.05x $314M $42M
-
Which has Higher Returns NUVB or NKTR?
Nektar Therapeutics has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of -301.29%. Nuvation Bio, Inc.'s return on equity of -52.16% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About NUVB or NKTR?
Nuvation Bio, Inc. has a consensus price target of $11.25, signalling upside risk potential of 19.68%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 157.2%. Given that Nektar Therapeutics has higher upside potential than Nuvation Bio, Inc., analysts believe Nektar Therapeutics is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 NKTRNektar Therapeutics6 1 0 -
Is NUVB or NKTR More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.
-
Which is a Better Dividend Stock NUVB or NKTR?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or NKTR?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 119.37x versus 45.88x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.119.37x -- $13.1M -$55.8M NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M
-
Which has Higher Returns NUVB or TERN?
Terns Pharmaceuticals, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of --. Nuvation Bio, Inc.'s return on equity of -52.16% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M -
What do Analysts Say About NUVB or TERN?
Nuvation Bio, Inc. has a consensus price target of $11.25, signalling upside risk potential of 19.68%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $53.56 which suggests that it could grow by 28.99%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Nuvation Bio, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 TERNTerns Pharmaceuticals, Inc.8 0 0 -
Is NUVB or TERN More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NUVB or TERN?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or TERN?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 119.37x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.119.37x -- $13.1M -$55.8M TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
